Loading stock data…
Humana Inc. (HUM)
$389.32-5.18 (-1.31%)
Market ClosedLast close Jul 24
Humana Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Humana Inc. in the Healthcare sector is trading at $389.32 with a market capitalization of $39.3B. Wall Street consensus targets $347.96 (24 analysts), implying a -10.6% move over the next 12 months. The stock is currently near its 52-week high of $428.88, remaining 48.8% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply -10.6% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $39.65B↑ | $32.52B↓ | $32.65B↑ | $32.39B↑ | $32.11B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $1.79B↑ | -$865.00M↓ | $302.00M↓ | $898.00M↓ | $1.85B |
| Net Income | $1.19B↑ | -$796.00M↓ | $195.00M↓ | $545.00M↓ | $1.24B |
Peer Comparison
JNJUNHPFE
Fundamentals
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, inclu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$39.32B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
34.96
Beta
Defensive asset. Lower volatility than the S&P 500.
0.68
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.91%
ROE
Average efficiency. Growth may require heavy reinvestment.
6.08%
Volume
Today's trading volume
740,260
Recent News
The Real Price of UnitedHealth Stock Is Two Years Away
The healthcare giant looks expensive on today's numbers, but a patient investor is effectively buying it at a significant discount to that price.
Can Humana Beat Q2 Earnings Estimates on Growing Premiums?
HUM enters Q2 earnings with strong premium and membership growth expectations, but rising medical costs and expenses could test its bottom line.
MOH Q2 Earnings Beat on Lower Operating Expenses, 2026 EPS View Raised
Molina beats Q2 earnings estimates as lower operating expenses offset weaker premium revenues, declining membership and softer investment income, while the company raises its 2026 earnings guidance.
Is Centene Stock a Smart Buy Ahead of Q2 Earnings? Key Estimates
CNC reports Q2 results July 28 as investors weigh improving profitability against membership declines and revenue pressure ahead of earnings.
Healthcare Services Group Q2 Earnings Call Highlights
Healthcare Services Group (NASDAQ:HCSG) reported second-quarter 2026 revenue of $470.8 million, with management citing disciplined execution, steady industry fundamentals and continued demand for outsourced services in long-term and post-acute care. Chief Executive Officer Ted Wahl said the company